---
title: "Unicycive Therapeutics 盘后跌超 10% 受 FDA 就制造缺陷发 CRL 影响"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291342556.md"
description: "UNCY.US 盘后跌 10.45% 至 4.2 美元，常规交易时段暴跌 39.09%。FDA 因第三方制造缺陷拒绝批准其肾病药物。"
datetime: "2026-06-30T23:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291342556.md)
  - [en](https://longbridge.com/en/news/291342556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291342556.md)
generator: "portal-rs"
---

# Unicycive Therapeutics 盘后跌超 10% 受 FDA 就制造缺陷发 CRL 影响

Unicycive Therapeutics(UNCY.US) 盘后跌超 10%，现报 4.2 美元。

公司收到 FDA 发出的完全回应函（CRL），针对重新提交的碳酸氧镧新药申请。FDA 指出第三方供应商存在未解决的制造缺陷，该供应商在审查期间未接受检查。FDA 未提出新的安全性或有效性问题，标签讨论仍在进行中。

该股在常规交易时段已暴跌**39.09%**，盘后继续走低。

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline](https://longbridge.com/en/news/294551506.md)
- [Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday](https://longbridge.com/en/news/295069777.md)
- [Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position](https://longbridge.com/en/news/291569499.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**